The discovery adds to growing evidence that the genome contains many functional peptides hidden within RNA molecules annotated as long noncoding RNAs. Long noncoding RNAs, or lncRNAs, are generally defined as transcripts longer than 200 nucleotides that do not serve as conventional templates for large proteins. Increasingly, however, scientists have found that some lncRNAs contain short open reading frames capable of producing micropeptides. These molecules can be only a few dozen or a few hundred amino acids long, yet they may regulate signaling complexes, membrane processes and gene expression. In this case, the researchers traced an immune-suppressive activity associated with the lncRNA gene USP30-AS1 to a peptide encoded within it. They designated the peptide USP30-AS1-encoded immune suppressor, abbreviated UEIS.

UEIS was found to be highly expressed in tumor-associated macrophages, immune cells that accumulate within cancers and can be reprogrammed by the tumor microenvironment. Macrophages are highly adaptable: depending on the signals they receive, they can support inflammation and attack abnormal cells, or promote tissue repair, blood-vessel formation and tumor growth. In the cancer setting, tumor-associated macrophages frequently acquire a protumorigenic state. Rather than efficiently supporting cytotoxic lymphocytes, they can help create an immune-permissive environment in which malignant cells survive, invade surrounding tissue and resist therapy. According to the study, UEIS contributes to this transition by suppressing macrophage interferon responses and thereby reducing the conditions needed for effective antitumor T cell activity.

The pathway targeted by UEIS normally functions as an intracellular alarm system for abnormal DNA. When tumor-derived DNA reaches the cell cytoplasm, it can be detected by the enzyme cGAS, which synthesizes the signaling molecule cyclic GMP–AMP. This molecule activates the adaptor protein STING, initiating a cascade involving the kinase TBK1 and downstream transcription factors that stimulate production of type I interferons. These interferons, including interferon-beta and related molecules, can strengthen antigen presentation, activate innate immune cells and help recruit and sustain T cells capable of attacking cancer. The pathway is therefore considered one of the most important bridges between the detection of tumor-associated DNA and the development of antitumor immunity.

The researchers found that UEIS is not simply present in macrophages at a constant level. Instead, it is induced after tumoral DNA activates the cGAS–STING pathway, but it appears relatively late in the response. This timing suggests that UEIS acts as a negative-feedback regulator. Early pathway activation can generate an interferon response, while later production of UEIS helps dampen that signal. Such feedback mechanisms are common in immune biology because uncontrolled interferon signaling can damage healthy tissue and trigger excessive inflammation. Cancer, however, may exploit this protective brake. By increasing UEIS after the initial alarm has sounded, tumor-associated macrophages can limit the duration or intensity of the immune response before it becomes sufficiently strong to support sustained tumor destruction.

At the molecular level, the study links UEIS to the formation of biomolecular condensates involving TBK1. Condensates are dynamic, membrane-free assemblies in which proteins and nucleic acids concentrate through multivalent interactions. They are increasingly recognized as organizing centers for signaling reactions, allowing pathway components to gather in the correct place and at the appropriate time. The researchers report that UEIS forms condensates with TBK1 and, through this interaction, interferes with the kinase’s association with STING. Because STING must engage TBK1 to efficiently transmit the signal generated by cytoplasmic DNA, disrupting that interaction effectively weakens the pathway downstream of DNA sensing. The result is reduced type I interferon signaling in macrophages.

The architecture of UEIS was also important to its activity. Experiments indicated that both an intrinsically disordered region and an alpha helix located at the extreme N terminus of the micropeptide were required for its function. Intrinsically disordered regions lack a single rigid three-dimensional structure and often enable flexible, multivalent interactions with several partners. They can be particularly important in the formation of biomolecular condensates because they provide repeated or adaptable binding surfaces. Alpha helices, by contrast, are structured elements that can create defined contact points within protein complexes. The findings suggest that UEIS may use its disordered region to support condensation while relying on its N-terminal helix to engage a signaling partner such as TBK1, although the precise atomic structure of the complex remains to be determined.

The therapeutic implications were tested with a peptide designed to disrupt UEIS–TBK1 condensation. Rather than attempting to eliminate the lncRNA or broadly inhibit the interferon pathway, the strategy focused on the physical interaction that gives UEIS its suppressive activity. The researchers report that the disrupting peptide inhibited UEIS function in tumor-associated macrophages. In experimental cancer models, treatment was associated with reduced tumor growth and a stronger response to immune checkpoint blockade. These results are significant because checkpoint inhibitors depend on an immune system capable of recognizing and attacking tumor cells. If macrophages suppress interferon signaling and maintain an immunosuppressive environment, blocking checkpoints alone may not be enough. Interrupting UEIS activity could help convert that environment into one more permissive for T cell function.

The findings position UEIS as a potential therapeutic target at the intersection of innate sensing, macrophage biology and cancer immunotherapy. They also illustrate why the search for cancer regulators cannot be limited to conventional protein-coding genes. A transcript previously categorized as noncoding can produce a short peptide that reorganizes a signaling pathway and changes the behavior of immune cells within tumors. Before the approach can be considered for clinical use, important questions will need to be addressed, including how selectively UEIS is expressed across cancers and normal tissues, whether disrupting its condensates causes unwanted inflammation, and how effectively the peptide can reach macrophages in human tumors. Nevertheless, the study offers a new explanation for how tumors attenuate cGAS–STING–type I interferon signaling and provides a possible way to strengthen immune checkpoint therapy by targeting a molecular brake embedded within a lncRNA.

Subject of Research: A micropeptide encoded by the lncRNA USP30-AS1 that suppresses cGAS–STING–type I interferon signaling in tumor-associated macrophages and promotes tumor growth.

Article Title: A micropeptide encoded by the lncRNA USP30-AS1 promotes tumor growth by attenuating cGAS–STING–type I IFN signaling in macrophages.

Article References: Wang, X., Zhang, Y., Ma, J. et al. “A micropeptide encoded by the lncRNA USP30-AS1 promotes tumor growth by attenuating cGAS–STING–type I IFN signaling in macrophages.” Nature Cancer 7, 1047–1063 (2026). https://doi.org/10.1038/s43018-026-01195-2

Image Credits: AI Generated

DOI: July 2026

Keywords: UEIS, USP30-AS1, micropeptide, long noncoding RNA, tumor-associated macrophages, cGAS–STING signaling, type I interferon, TBK1, biomolecular condensates, immune checkpoint blockade, cancer immunotherapy.

The human genome is predominantly composed of non-protein-coding DNA sequences formerly dubbed “junk” due to their elusive functions and seemingly silent nature. However, with the advent of advanced genomic technologies, it has become evident that many of these sequences give rise to functional lncRNAs—transcripts longer than 200 nucleotides that regulate gene expression at multiple levels. Unlike protein-coding genes, lncRNAs display remarkable evolutionary dynamics, often being species-specific or lineage-specific, thus reflecting their recent emergence and rapid adaptation. This study elucidates the evolution of cancer-associated lncRNAs, revealing their ability to infiltrate and manipulate ancient biological networks governing cellular homeostasis.

Through comprehensive genomic comparison across 17 diverse animal species, encompassing nearly 18,000 identified lncRNAs, the research team reconstructed the evolutionary timeline of these regulatory RNAs. The investigators discovered that many lncRNAs implicated in cancer originated from smaller, initially non-functional microRNA-like fragments. Over millions of years, these fragments expanded in length and complexity, incorporating new genetic sequences and regulatory motifs. This evolutionary trajectory allowed them to become embedded within primordial signaling pathways conserved for over 400 million years, including those controlling metabolism, stress responses, and programmed cell death—core functions often deregulated in cancers.

A seminal example highlighted in the study is the lncRNA known as MIR497HG. This molecule likely emerged approximately 29 million years ago in a common ancestor shared by humans and other primates, initially functioning as a microRNA element. Strikingly, a single nucleotide mutation—a transversion from adenine (A) to thymine (T)—acted as a molecular switch, enabling bursts of RNA transcription that gave rise to the full-length MIR497HG transcript unique to humans. Over evolutionary time, MIR497HG’s expanded form incorporated itself within ancient regulatory circuits, illustrating how new genetic elements co-opt and repurpose deeply conserved cellular machinery.

The integration of MIR497HG into the AMPK-ferroptosis axis exemplifies this adaptive phenomenon. AMPK, a master metabolic sensor, and ferroptosis, a regulated form of iron-dependent cell death, are fundamental processes maintaining cellular homeostasis. The study demonstrated that MIR497HG influences these pathways, affecting cancer cell proliferation and survival. Functional experiments in human stem cells and various cancer lines revealed that suppressing MIR497HG expression accelerates tumor growth, while restoring its activity inhibits proliferation, signifying its tumor-suppressive role. This functional repurposing underscores the potential of lncRNAs as modulators of critical cancer regulatory machineries.

At a molecular level, MIR497HG appears to exert its effects by engaging with the AMPK signaling cascade and ferroptotic regulators, altering their activity in a manner conducive to tumorigenesis when dysregulated. This finding opens a novel mechanistic window into how recently evolved RNA elements can rapidly integrate into ancient cellular frameworks, thereby expanding the regulatory complexity of gene expression and cellular behavior. Such rapid evolutionary innovation also introduces new vulnerabilities exploitable for therapeutic intervention, particularly in cancers where MIR497HG expression is diminished.

Beyond MIR497HG, the broader evolutionary landscape presented suggests that numerous human-specific lncRNAs may have undergone similar processes of sequence expansion, alternative splicing, and integration into ancient biological pathways. This evolutionary model aligns with the principles of neutral evolution, wherein genetic innovations can arise and persist within permissive genomic environments before becoming functionally entrenched. The gradual but consequential incorporation of these RNAs enriches the regulatory fabric of cells but may also render gene networks more susceptible to dysregulation and disease.

The researchers employed cutting-edge comparative genomics, transcriptomic profiling, and molecular biology techniques to uncover the evolutionary dynamics and biological significance of these lncRNAs across species. Their data reveal not only the scale of previously unappreciated lncRNA diversity but also provide a temporal framework highlighting evolutionary milestones that shaped cancer-relevant gene regulation. Insights gained from such integrative analyses offer a powerful paradigm for identifying novel biomarkers and drug targets that are evolutionarily conserved yet dynamically regulated in human disease contexts.

Importantly, this study bridges a vital gap between evolutionary genetics and translational cancer research. By tracing the molecular origins and functional assimilation of lncRNAs into essential signaling networks, it challenges researchers to reconsider the roles of noncoding genomic elements far beyond passive bystanders. It advocates for evolutionary perspectives as potent tools in unraveling the etiology of cancer and in guiding the development of targeted therapies that leverage the inherent evolutionary vulnerabilities of tumor cells.

Looking ahead, MIR497HG’s distinct expression pattern—abundant in normal tissues but reduced in cancers—suggests its promising utility as a diagnostic biomarker that could predict cancer progression and patient prognosis. Moreover, targeting the AMPK-ferroptosis axis modulated by MIR497HG may provide a strategic therapeutic window for multiple cancer types, potentially improving clinical outcomes. These findings underscore a new frontier in personalized medicine, where evolutionary-informed molecular targets redefine cancer treatment paradigms.

In sum, this research illuminates the remarkable evolutionary fitness of lncRNAs as dynamic, regulatory entities capable of bridging newly emerged sequences with ancient, conserved cellular architectures. It affirms that evolutionary innovation, far from being random genetic noise, is a carefully orchestrated process facilitating molecular complexity and adaptability. As the catalog of functionally relevant lncRNAs continues to expand, fueled by integrative evolutionary and molecular approaches, we move closer to unveiling the full repertoire of genomic elements driving human health and disease.

The authors of this study hail from an international consortium including Arizona State University, Tianjin Medical University, and other leading institutions. Their collaborative efforts highlight the importance of interdisciplinary research in uncovering fundamental biological truths. Their work not only enriches our understanding of genome evolution and cancer biology but also sets a foundation for future investigations poised to translate evolutionary insights into clinical breakthroughs.

Subject of Research: People
Article Title: Rapid Evolution of lncRNAs Introduces Novel Regulatory Inputs into Ancestral Cancer Pathways
News Publication Date: 1-Jul-2026
Web References: https://doi.org/10.1126/sciadv.aeb5510
References: Scientific article published in Science Advances, DOI: 10.1126/sciadv.aeb5510
Keywords: long noncoding RNAs, lncRNA evolution, cancer biology, gene regulation, microRNA, AMPK signaling pathway, ferroptosis, tumor proliferation, comparative genomics, evolutionary biology, cancer biomarkers, molecular oncology